![]() | |
Clinical data | |
---|---|
Routes of administration | Oral [1] |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C29H40N2O3 |
Molar mass | 464.650 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Lapisteride ( INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase. [2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia, [2] [3] but was never marketed.
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral [1] |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C29H40N2O3 |
Molar mass | 464.650 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Lapisteride ( INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase. [2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia, [2] [3] but was never marketed.